Compile Data Set for Download or QSAR
Report error Found 123 Enz. Inhib. hit(s) with all data for entry = 8505
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254486(US9468661, 64)
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254498(US9468661, 76 | US9468661, 109)
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254483(US9468661, 61)
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254475(US9468661, 53)
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254488(US9468661, 66)
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254471(US9468661, 49)
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254528(US9468661, 106)
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254454(US9468661, 32)
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254485(US9468661, 63)
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254462(US9468661, 40)
Affinity DataIC50: 7nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254497(US9468661, 75 | US9468661, 108)
Affinity DataIC50: 7nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254478(US9468661, 56)
Affinity DataIC50: 8nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254459(US9468661, 37)
Affinity DataIC50: 11nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254468(US9468661, 46)
Affinity DataIC50: 12nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254496(US9468661, 74 | US9468661, 78)
Affinity DataIC50: 12nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254527(US9468661, 105)
Affinity DataIC50: 14nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254458(US9468661, 36 | US9468661, 121)
Affinity DataIC50: 14nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254481(US9468661, 59)
Affinity DataIC50: 14nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254452(US9468661, 30)
Affinity DataIC50: 15nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254526(US9468661, 104)
Affinity DataIC50: 16nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254516(US9468661, 94)
Affinity DataIC50: 16nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254479(US9468661, 57)
Affinity DataIC50: 17nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254515(US9468661, 93)
Affinity DataIC50: 19nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254449(US9468661, 27)
Affinity DataIC50: 19nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254487(US9468661, 65)
Affinity DataIC50: 20nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254501(US9468661, 79 | US9468661, 81)
Affinity DataIC50: 21nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254514(US9468661, 92)
Affinity DataIC50: 24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254458(US9468661, 36 | US9468661, 121)
Affinity DataIC50: 25nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254461(US9468661, 39)
Affinity DataIC50: 27nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254470(US9468661, 48)
Affinity DataIC50: 27nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254497(US9468661, 75 | US9468661, 108)
Affinity DataIC50: 27nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254521(US9468661, 99)
Affinity DataIC50: 32nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254453(US9468661, 31)
Affinity DataIC50: 32nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254469(US9468661, 47)
Affinity DataIC50: 35nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254495(US9468661, 73 | US9468661, 77)
Affinity DataIC50: 35nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254494(US9468661, 72)
Affinity DataIC50: 36nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254480(US9468661, 58)
Affinity DataIC50: 39nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254460(US9468661, 38)
Affinity DataIC50: 40nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254536(US9468661, 114)
Affinity DataIC50: 40nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254532(US9468661, 110)
Affinity DataIC50: 41nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254466(US9468661, 44)
Affinity DataIC50: 41nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254467(US9468661, 45)
Affinity DataIC50: 43nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254451(US9468661, 29)
Affinity DataIC50: 46nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254513(US9468661, 91)
Affinity DataIC50: 46nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254498(US9468661, 76 | US9468661, 109)
Affinity DataIC50: 49nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254463(US9468661, 41)
Affinity DataIC50: 51nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254529(US9468661, 107)
Affinity DataIC50: 52nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254491(US9468661, 69)
Affinity DataIC50: 53nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254512(US9468661, 90)
Affinity DataIC50: 53nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM254474(US9468661, 52)
Affinity DataIC50: 56nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

Displayed 1 to 50 (of 123 total ) | Next | Last >>
Jump to: